Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges
Pharmaceutics · 15.07.2026 · 18 (7) · 861
DOI: 10.3390/pharmaceutics18070861 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 15.07.2026. Verfasst von Shasha Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province grant.
Abstract (Originalsprache)
Wet age-related macular degeneration (wAMD) is characterized by choroidal neovascularization (CNV) and remains a major cause of severe vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the current standard of care for wAMD. However, repeated injections are associated with poor adherence, procedure-related complications, and a substantial cumulative treatment burden. Topical nanocarrier-based systems have therefore attracted increasing attention as needle-free approaches for improving posterior segment drug exposure. Complementing broader reviews of ocular nanomedicine, this review specifically examines topical nanocarrier-mediated posterior segment delivery for wAMD, with a focus on three representative platforms: liposomes, polymeric nanoparticles, and polymeric micelles. These systems are engineered through the optimization of particle size, surface properties, drug-loading strategies, and functional modifications to improve payload stability, ocular surface residence, tissue penetration, and lesion-relevant delivery. By integrating formulation design, ocular barrier transport, ocular posterior segment bioavailability, and translational feasibility in the context of wAMD, this review provides a disease-focused and application-oriented perspective that complements existing broader reviews of ocular nanocarriers and ophthalmic nanomedicine. We summarize current evidence from preclinical and translational studies and discuss major barriers limiting clinical application, including insufficient posterior segment drug exposure, dose–safety trade-offs, pharmacokinetic instability, limited targeting efficiency, and challenges in delivering macromolecular biologics, such as anti-VEGF antibodies and fusion proteins. At present, topical nanocarrier-based strategies remain investigational, but they hold potential for development as therapeutic approaches for wAMD. Key priorities for future development include quantitative posterior segment pharmacokinetic/pharmacodynamic evaluation, long-term safety assessment, payload-specific carrier design, scalable manufacturing, and clinically relevant efficacy endpoints. This review provides a focused framework for the rational design and translational assessment of nanocarrier-based topical strategies for wAMD management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province grant
- Research Funds of the State Key Laboratory of Ophthalmology
- Program for Supporting and Cultivating Outstanding Scientific and Technological Talents, Zhongshan Oph-thalmic Center, Sun Yat-sen University
- GBRCE for Major Blinding Eye Diseases Prevention and Treatment
- National Key R&D Program of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Wang, S., Liu, L., Zeng, X., Tang, C., Chen, W., Li, X., & Lu, W. (2026). Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges. Pharmaceutics, 18(7), 861. https://doi.org/10.3390/pharmaceutics18070861
Vancouver
Wang S, Liu L, Zeng X, Tang C, Chen W, Li X, et al. Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges. Pharmaceutics. 2026;18(7):861. doi:10.3390/pharmaceutics18070861
BibTeX
@article{Wang2026,
author = {Wang, Shasha and Liu, Linfei and Zeng, Xiaoling and Tang, Chonghui and Chen, Wei and Li, Xuri and Lu, Weisi},
title = {Nanocarrier-Mediated Non-Invasive Drug Delivery for Wet Age-Related Macular Degeneration: Advances and Translational Challenges},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {861},
doi = {10.3390/pharmaceutics18070861}
}
EUVIMED